This European company doubled its value in just six weeks
By Steve Goldstein
Few companies have seen a stock price roller-coaster quite like Adyen, the Dutch payment processing firm.
Adyen (NL:ADYEN) (ADYEY), which has a devoted following on the social-media service X that is unusual for a European company, has seen its stock double off the intraday low in late October.
That's coming in the same year in which its stock saw a one-day 39% slide, following a first-half profit warning. Adyen has reeled from the aggressive price-cutting moves from rival PayPal's (PYPL) Braintree Payments division.
Last week, analysts at Citi gave the firm a double upgrade, to buy from sell, and moved their price target all the way up to EUR1,400 from EUR695.
"We maintain that increased competition is structural, but see better data capabilities from Adyen's single platform and strong unified commerce offering (vs key competitors not having an on-premise presence) in providing better customer intelligence, improving authorization rates. This is supported by our proprietary survey of 50 large online merchants," they said.
Adyen shares rose another 2% on Monday.
Also in the spotlight, Solvay (BE:SOLB) specialties chemicals spinoff Syensquo rose 12% in its trading debut.
The broader Stoxx Europe 600 XX:SXXP was nearly flat, with trading muted ahead of Tuesday's U.S. CPI reading.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
12-11-23 0806ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth